ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.